Portal de Periódicos da CAPES

Task Force 7: Arrhythmias

2005; Elsevier BV; Volume: 45; Issue: 8 Linguagem: Inglês

10.1016/j.jacc.2005.02.014

1558-3597

Douglas P. Zipes, Michael J. Ackerman, N.A. Mark Estes, Augustus O. Grant, Robert J. Myerburg, George Van Hare,

Cardiac Arrhythmias and Treatments

The prevention and management of QT interval prolongation and torsades de pointes often depends on the underlying etiology. Drugs and electrolyte imbalances are the major causes of acquired long QT syndrome, and prevention strategies include identifying and discontinuing or substituting the offending drug and correcting electrolyte abnormalities. Lifestyle modification, genetic testing, and β-adrenergic receptor blockade are risk mitigation strategies for patients with the congenital long QT syndrome. Left cardiac sympathetic denervation, implantable cardioverter-defibrillator, magnesium sulfate and overdrive cardiac pacing are currently used in the management of TdP, although a significant number of cases are not adequately managed. This chapter discusses the approaches and current therapies for the prevention and management of long QT syndrome. The chapter also explores novel approaches such genome editing, RNA interference, and hormone therapy in the management of QT interval prolongation and torsades de pointes.